system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Animals, Carcinogenesis, Carcinoma, Hepatocellular, Cell Line, Tumor, Cell Movement, Cell Proliferation, Clone Cells, Female, Gene Expression Regulation, Neoplastic, Gene Knockdown Techniques, Gene Silencing, Humans, Kaplan-Meier Estimate, Liver Neoplasms, Male, Mice, Mice, Inbred BALB C, Mice, Nude, Middle Aged, Neoplasm Invasiveness, Prognosis, RNA, Long Noncoding, Up-Regulation, Xenograft Model Antitumor Assays.
user
Does hOX Antisense lincRNA HOXA-AS2 promote Tumorigenesis of Hepatocellular Carcinoma? Context: Recent studies reveal that long non-coding RNAs (LncRNAs) play critical roles in the proliferation and migration of human cancer. Previous report has shown that LncRNA HOXA-AS2 was involved in carcinoma processes. However, the expression and biological function of HOXA-AS2 in hepatocellular carcinoma (HCC) are poorly understood. Quantitative real-time PCR (qRT-PCR) was performed to detect the expression of HOXA-AS2 in HCC tissues and cell lines. The relation between lncRNA HOXA-AS2 expression and clinicopathological characteristics was assessed by chi-square test. The prognosis was analyzed using Kaplan-Meier method, and compared differences between the two groups by log-rank test. The biological function of HOXA-AS2 on HCC cells were determined both in vitro and in vivo. In the present study, we found that HOXA-AS2 expression was increased in HCC tissues and adjacent normal tissues and high HOXA-AS2 expression was associated with bigger tumor size, advanced tumor stage, and shorter survival time. Knockdown of HOXA-AS2 significantly inhibited HCC cell proliferation and invasion and resulted in an increase of apoptosis. Furthermore, inhibition of HOXA-AS2 in HCC cells significantly repressed tumorigenicity in nude mice.
assistant
Our results indicated that the inhibition of HOXA-AS2 in HCC cells significantly inhibited cell proliferation in vitro and in vivo, which might provide a potential possibility for targeted therapy of HCC. Final Decision: yes